Canine Skin Tumors Study Guide

Overview and Clinical Importance

Cutaneous tumors represent one of the most frequently encountered neoplastic conditions in canine practice and constitute a significant portion of NAVLE examination content. Skin tumors account for approximately 30% of all tumors diagnosed in dogs, making them the most common tumor type encountered.

This study guide covers four major categories of canine skin tumors: cutaneous mast cell tumors (MCTs) - the most common malignant skin tumor; lipomas - the most common benign mesenchymal tumor; squamous cell carcinoma (SCC) - a common epithelial malignancy; and histiocytic tumors - ranging from benign histiocytomas to aggressive histiocytic sarcomas.

Section 1: Cutaneous Mast Cell Tumors (MCTs)

Definition and Epidemiology

Mast cell tumors (MCTs) are hematopoietic neoplasms derived from mast cells, which are tissue-resident cells of the immune system involved in allergic and inflammatory responses. MCTs represent the most common malignant skin tumor in dogs, accounting for 11% of all skin cancers and 16-21% of all cutaneous tumors.

Breed Predispositions

Clinical Presentation

MCTs are often called the "great imitator" because they can mimic virtually any cutaneous lesion. They present with highly variable clinical appearances:

• Solitary or multiple cutaneous nodules (11-14% present with multiple masses)
• Well-circumscribed, alopecic, dome-shaped masses
• Erythematous, pruritic, edematous lesions
• Ulcerated masses (occurs in up to 30% of cases)
• Rapidly growing, infiltrative tumors

Anatomic Distribution

• Trunk, perineum, inguino-genital regions: approximately 50%
• Limbs: approximately 40%
• Head and neck: approximately 10%

Darier Sign and Paraneoplastic Effects

Mast cell degranulation releases histamine, heparin, and other vasoactive substances, causing characteristic clinical signs:

• Darier sign: Wheal and flare reaction when tumor is manipulated
• Local effects: Erythema, edema, pruritus, ulceration
• Gastrointestinal effects: Gastric ulceration, vomiting, melena (due to histamine stimulating H2 receptors)
• Systemic effects: Hypotension, coagulopathy (due to heparin release)

Diagnosis

Fine Needle Aspiration and Cytology

FNA with cytologic evaluation is highly accurate for MCT diagnosis. A 26-gauge needle is recommended to reduce blood contamination and improve diagnostic accuracy.

Cytologic Features

• Round cells with distinct cytoplasmic borders
• Metachromatic cytoplasmic granules (purple with Romanowsky stains)
• Background granules from ruptured cells
• Variable nuclear size and shape in poorly differentiated tumors
• Eosinophils frequently present

Histopathologic Grading Systems

Histologic grading is the primary prognostic tool for canine cutaneous MCTs. Two grading systems are currently in use:

Patnaik Grading System (3-Tier, 1984)

Kiupel Grading System (2-Tier, 2011)

The Kiupel system was developed to reduce interobserver variability. A tumor is classified as HIGH GRADE if ANY ONE of the following criteria is present:

• 7 or more mitotic figures in 10 high-power fields (HPF)
• 3 or more multinucleated cells (3+ nuclei) in 10 HPF
• 3 or more bizarre nuclei in 10 HPF
• Karyomegaly: nuclear diameter varies by at least 2-fold in 10% or more of cells

If NONE of the above criteria are present, the tumor is classified as LOW GRADE.

Memory Aid - KIUPEL High Grade Criteria: "7-3-3-K" 7 = 7 or more mitoses/10 HPF 3 = 3 or more multinucleated cells/10 HPF 3 = 3 or more bizarre nuclei/10 HPF K = Karyomegaly (2-fold size variation in 10%+ of cells)

Staging

Staging is essential for prognosis and treatment planning. The regional lymph node aspiration is the most commonly positive staging test, even when nodes appear normal (38-46% of normal-sized lymph nodes harbor metastases).

Recommended Staging Tests

• Regional lymph node aspiration: Perform BEFORE tumor excision
• Abdominal ultrasound: Evaluate spleen and liver with guided FNA if abnormal
• CBC and chemistry panel: Assess overall health; buffy coat smear for circulating mast cells
• Thoracic radiographs: Pulmonary metastasis uncommon but should be ruled out

Treatment

Prognosis

Section 2: Lipomas and Infiltrative Lipomas

Definition and Epidemiology

Lipomas are the most common benign mesenchymal tumor in dogs, composed of mature adipocytes. They are typically slow-growing, soft, movable subcutaneous masses in older, often overweight dogs.

Types of Adipose Tissue Tumors

Breed Predispositions

• Labrador Retriever: Most commonly affected breed
• Other predisposed breeds: Doberman Pinscher, Miniature Schnauzer, Cocker Spaniel, Dachshund
• Risk factors: Middle-aged to older dogs, obesity, female predisposition

Clinical Presentation and Diagnosis

Simple lipomas: Soft, fluctuant, well-circumscribed, freely movable subcutaneous masses on trunk and proximal limbs. Infiltrative lipomas: Poorly demarcated, diffuse soft tissue swelling that may cause dysfunction due to mechanical interference or pressure pain.

Cytology: Clear to slightly yellow, oily fluid with clusters of mature adipocytes showing "signet ring" appearance.

Treatment and Prognosis

Simple lipomas: Marginal surgical excision is curative; monitoring acceptable if not causing problems. Infiltrative lipomas: Wide surgical excision or amputation; radiation therapy for incomplete margins (MST greater than 40 months with radiation). Not all lipomas require treatment!

Section 3: Cutaneous Squamous Cell Carcinoma

Definition and Epidemiology

Squamous cell carcinoma (SCC) is a malignant tumor arising from keratinocytes, accounting for approximately 5% of all cutaneous tumors in dogs. Cutaneous SCC is typically locally aggressive with low metastatic potential, except for the digital (subungual) form which is more aggressive.

Risk Factors and Breed Predispositions

• Cutaneous/Actinic SCC: Light-skinned breeds (Dalmatian, Bull Terrier, Beagle, Whippet, White Boxer); UV exposure; unpigmented skin
• Digital/Subungual SCC: Large breeds with dark coats (Giant Schnauzer, Standard Poodle, Rottweiler, Black Labrador, Gordon Setter)
• Nasal Planum SCC: Dogs with unpigmented nasal planum; sun-induced

Clinical Presentation

Cutaneous SCC

• Ulcerated, erythematous plaques on ventral abdomen, inguinal area, and poorly pigmented skin
• Often multiple lesions in sun-damaged skin
• Locally aggressive but low metastatic rate (less than 10%)

Digital SCC

• Swollen toe with nail loss or deformation
• Lameness and pain on palpation
• Bone lysis visible on radiographs
• 56% risk of developing new tumors on different digits

Treatment and Prognosis

Section 4: Histiocytic Tumors

Overview

Histiocytic tumors represent a spectrum of diseases ranging from benign cutaneous histiocytoma to highly aggressive histiocytic sarcoma. Understanding this spectrum is critical for accurate diagnosis and prognosis.

Cutaneous Histiocytoma

Definition and Epidemiology

Cutaneous histiocytoma is a benign tumor of Langerhans cells (epidermal dendritic cells) affecting young dogs (less than 4 years old). The hallmark of this tumor is spontaneous regression within 1-3 months due to T-cell mediated immune response.

Breed Predispositions

• Commonly affected breeds: Boxer, Bulldog, Scottish Terrier, Greyhound, Doberman Pinscher, Cocker Spaniel
• Age: Typically less than 4 years old (median age 2 years)

Clinical Presentation

• Rapidly growing, dome-shaped, alopecic "button" lesion
• Typically solitary (multiple histiocytomas rare)
• Common locations: head, ears (pinnae), limbs
• Often erythematous and may ulcerate
• Usually less than 2 cm in diameter

Diagnosis

Cytology: Round cells with abundant pale blue cytoplasm that is NON-GRANULAR (key differentiator from MCT). Nuclei are round to indented with fine chromatin. Small lymphocytes may be interspersed (indicating regression).

Treatment and Prognosis

• Watch and wait: Preferred approach - most regress spontaneously within 1-3 months
• Surgical excision: Reserved for tumors that do not regress, become ulcerated, or cause owner concern
• Prognosis: Excellent - benign tumor with spontaneous resolution

Histiocytic Sarcoma

Definition and Epidemiology

Histiocytic sarcoma (HS) is an aggressive malignancy of dendritic cells or macrophages. It represents one of the most aggressive cancers in dogs with generally poor prognosis. Three forms are recognized based on distribution and cell of origin.

Forms of Histiocytic Sarcoma

Breed Predispositions

• Bernese Mountain Dog: Highest risk (up to 25% develop HS); hereditary component identified
• Flat-Coated Retriever: Strong predisposition; second most commonly affected breed
• Golden Retriever, Labrador Retriever: Also predisposed
• Rottweiler, Miniature Schnauzer, Pembroke Welsh Corgi: Increased risk

Clinical Signs

• Localized HS: Lameness (periarticular), soft tissue mass, respiratory signs (pulmonary)
• Disseminated HS: Lethargy, weight loss, anorexia, hepatosplenomegaly, lymphadenopathy
• Hemophagocytic HS: Severe regenerative anemia, pallor, weakness, splenomegaly, thrombocytopenia

Diagnosis

• Cytology: Large, pleomorphic round cells with abundant pale cytoplasm; may see phagocytosis of RBCs in hemophagocytic form
• Histopathology with immunohistochemistry: Required for definitive diagnosis; CD18+ confirms histiocytic origin
• Staging: CBC, chemistry, thoracic radiographs, abdominal ultrasound, CT for extent assessment

Treatment

Memory Aid - Histiocytic Tumor Spectrum: "HISTIO = Harmless In Some, Terrible In Others" Harmless: Cutaneous Histiocytoma (benign, self-resolves) Terrible: Histiocytic Sarcoma (aggressive, poor prognosis) Young dog + Button tumor + Head/Ear = Histiocytoma (good!) Bernese/Flat-Coat + Lameness + Weight loss = Histiocytic Sarcoma (bad!)

Summary: Comparison of Major Canine Skin Tumors